Onychomycosis Treatment Market Size & Share 2025 - 2034

Onychomycosis Treatment Market Size

The global onychomycosis treatment market was estimated at USD 4.2 billion in 2024. The market is expected to grow from USD 4.3 billion in 2025 to USD 6.9 billion in 2034, at a CAGR of 5.3%. The high growth of market is attributed to increasing prevalence of onychomycosis globally, growing awareness about the potential threats of onychomycosis, and the increase in adoption of drug therapies for the treatment of onychomycosis. In addition, the increasing cases of age-related onychomycosis will further contribute market growth during the analysis period.

The market is further strengthened by the growing popularity of online pharmacies and the rise in consumer preference for self-treatment, owing to increasing availability of over the counter (OTC) drugs for onychomycosis. E-commerce platforms such as Amazon and eBay, along with dedicated pharmacy websites and retail pharmaceutical stores, have made it easier for consumers to directly access antifungal drugs, contributing to market growth. Additionally, the increasing prevalence of diabetes raises the risk of onychomycosis, as diabetic patients are more susceptible to the condition due to compromised immune systems and poor circulation. For instance, with over 400 million people currently affected by diabetes, the demand for onychomycosis treatments within this patient group is rising, further driving market expansion.
 

Further, the rising geriatric population increases the risk of developing onychomycosis. Thus, with the rapidly growing aging population the incidence of nail fungal infection increases, that further contribute to market growth. As an example, the report published by United Nations states that the number of people aged 60 and above will double by 2050 to reach 2.1 billion. Moreover, increasing awareness and cosmetic concerns among consumers regarding nail infections are leading to a growing focus on the aesthetic care of hands and feet, thereby contributing to market growth.  
 

Onychomycosis, also identified as tinea unguium, is a fungal infection of the fingernails or toenails that may comprise any component of the nail unit. The symptoms include thickening, discoloration, and separation from the nail bed. Onychomycosis treatment includes creams, medicated nail polish, and oral anti-fungal drugs. The high availability of different onychomycosis treatment options in the market will propel industry growth.
 

Onychomycosis Treatment Market Trends

• The increasing demand for cosmetic procedures coupled with regulatory approvals and product launches contribute to the growth of the market.
   
• Regulatory authorities such as the U.S. FDA and European Medicines Agency (EMA) continue to approve novel treatments, encouraging market growth. For instance, the approval of Jublia (efinaconazole) and Kerydin (tirbanibulin) has contributed significantly to the market's expansion.
   
• Thus, the rising awareness about onychomycosis with significant improvements in treatment modalities, including the development of topical antifungal agents, oral therapies, and laser treatments boost market growth.
   
• Moreover, the advancement in novel drug formulation, with improved drug delivery mechanisms, and availability of advanced diagnostic tools, are the factors that improves the treatment outcomes. This has led to attract more patients to pharmaceutical therapies for onychomycosis thereby contributing market growth.
   
• Further, the increasing risk of onychomycosis owing to rising incidence of comorbidities such as diabetes, peripheral vascular disease and psoriasis significantly increase susceptibility to the disease. For instance, according to CDC, more than 11% of U.S. population has diabetes, out of this around 30% of diabetic population develop fungal nail infections.
   
• Also, the growing consumer preference for aesthetic wellness for discolored or deformed nails, especially in urban and younger demographics, increases the adoption of onychomycosis drugs thereby contributing to market growth. In addition, the growing aesthetic concerns leads to increasing spending on personal care, raising demand for effective and cosmetically acceptable antifungal treatments, that support market growth.
   
• Lastly, the expanding healthcare access in developing countries such as India, Brazil, and China are expanding the market base. Additionally, the growing adoption of tele dermatology and online purchase of prescription/OTC treatments through e-pharmacies drives the growth of the market.
   

Trump Administration Tariffs

• The imposition of tariffs on imports from countries such as China including pharmaceutical ingredients, packaging materials, and diagnostic equipment may increase the cost of raw materials and topical/oral antifungal formulations used in onychomycosis treatment. These tariffs may also disrupt the supply chain, as many manufacturers of antifungal therapies and nail care devices depend on Chinese suppliers for affordable active pharmaceutical ingredients (APIs), transdermal delivery components, and diagnostic kits.
   
• As a result, companies operating in the onychomycosis treatment market may need to reassess their sourcing strategies to reduce reliance on Chinese vendors. This may prompt a strategic shift toward alternative supply bases such as India, Vietnam, and Eastern European nations, which are increasingly being explored as cost-effective and politically neutral manufacturing hubs.
   
• Tariffs may also disrupt the demand forecasting and inventory planning within the global supply chain, affecting the accuracy of just-in-time ordering and leading to potential delays in product availability.
   
• The U.S. primarily imports generic medications from countries like India and China. Tariffs on these imports could lead to increased costs and potential shortages, as the added costs are generally passed on to consumers.
   
• In the short term, this realignment could introduce challenges such as delays in product availability, increased operational expenses due to supply chain diversification, and potential interruptions in after-sales support for diagnostic tools, treatment devices (e.g., laser systems), and topical/oral therapeutics.
   

Onychomycosis Treatment Market Analysis

In 2021, the global market was valued at USD 3.7 billion. The following year, it saw a slight increase to USD 3.8 billion, and by 2023, the market further climbed to USD 4 billion.
 

Based on treatment type, the global onychomycosis treatment market is divided into drugs, laser and photodynamic therapy and surgery. The drugs segment is further sub-segmented into oral antifungal drugs and topical antifungal drugs. The drugs segment dominated the market and was valued at USD 3.2 billion in 2024.
 

• The growth of drugs segment is driven by the oral antifungal agents or drugs that have been identified as the most suitable and first-line therapy for onychomycosis.
   
• Additionally, the most commonly used oral drugs for the treatment of onychomycosis are itraconazole, terbinafine, griseofulvin, and ketoconazole.
   
• Moreover, the wide availability of these drugs in pharmacies further propels the overall market growth.
   
• Furthermore, with the growing awareness of nail health and the cosmetic concerns associated with onychomycosis, there has been a surge in demand for drugs that can effectively treat the condition that have fueled growth in the drugs segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the disease type, the global onychomycosis treatment market is categorized into distal subungual onychomycosis (DSO), proximal subungual onychomycosis (PSO), white superficial onychomycosis (WSO), and other disease types. The distal subungual onychomycosis segment accounted for the highest market share of 68.3% in 2024.
 

• DSO represents the most common type of onychomycosis. It is also more common in smokers and in those who use occlusive footwear.
   
• Moreover, the aging demographic is more susceptible to onychomycosis due to factors such as reduced peripheral circulation, diabetes, and weakened immune systems. As the global population ages, the incidence of DSO is expected to rise, thereby increasing the demand for treatments, that boosts market growth.
   
• Further, the patients with diabetes are more likely to develop DSO which is more severe and recurrent in immunocompromised patients. Thus, the increasing cases of DSO owing to rise in comorbidities increasing the demand for systemic and topical anti-fungal treatments, thereby driving the market growth.
   
• Thus, as the most prevalent type of infection, the DSO segment accounted for the largest market share in 2024 and is expected to maintain this trend in the coming years, thereby driving overall market growth.
   

Based on the gender, the global onychomycosis treatment market is categorized into male and female. The female segment dominated the market in 2024 and is anticipated to grow with a significant CAGR of 5.2% during the analysis period.
 

• Onychomycosis is more commonly seen in women compared to men. This is due to various lifestyle, environmental, and biological factors that increase the vulnerability of women to fungal infections.
   
• Women typically place greater importance on the appearance of their nails, making them more likely to seek treatment for onychomycosis. The cosmetic discomfort caused by discolored, thickened, and damaged nails serves as a significant driver for treatment among female patients.
   
• "With rising disposable incomes, women are increasingly investing in healthcare, including dermatological treatments. This trend is accelerating the adoption of therapies for conditions such as onychomycosis, as women place greater emphasis on self-care and preventive health.
   

Based on the end use, the global onychomycosis treatment market is categorized into hospitals, dermatology clinics, homecare settings, and ambulatory surgical centers. The dermatology clinics segment dominated the market in 2024 and is anticipated to reach USD 3 billion by 2034.
 

• Dermatology clinics are at the forefront of offering advanced treatment methods for onychomycosis, including topical antifungal treatments, oral medications, and laser therapies. Thus, the increasing availability of innovative treatments, such as laser therapy and newer oral antifungals, has boosted the demand for specialized dermatology services.
   
• Furthermore, dermatology clinics are not solely concerned with medical attention, they also offer cosmetic services. Onychomycosis leads to cosmetic problems because of discoloration and nail deformities. There is a rising demand for aesthetic procedures aimed at improving the appearance of the nails and preventing infections. This has increased the number of clients seeking treatment at dermatology clinics, thus contributing to market expansion.
   
• Also, the availability of insurance dermatological treatments has enhanced the accessibility of care services for onychomycosis. In recent times, more insurance providers have started to cover specific treatments, including oral and topical antifungal medications and lasers, which has resulted in increasing patient attendance in dermatology clinics.
   

In 2024, the U.S. held a significant position in the North America onychomycosis treatment market and was valued at USD 1.6 billion.
 

• High regional growth is attributed to increasing awareness about onychomycosis infection and the availability of several treatment options in the region.
   
• Moreover, an increasing desire for better aesthetic appeal and hygiene also increases the demand for timely clinic visits and early detection of such infections.
   
• Furthermore, availability of effective treatment may reduce the rate of transmission and related morbidities. Thus, all these factors are expected to propel the North America market growth over the analysis timeframe.
   

Germany onychomycosis treatment market shows strong growth potential in the Europe market.
 

• Patients in Germany are increasingly opting for topical treatments for onychomycosis, such as antifungal nail lacquers and creams, over oral medications due to their convenience and fewer side effects, contributing to the overall market growth.
   
• Furthermore, Germany has a developed healthcare system with most medical services offered as part of the statutory health insurance system (SHI). Onychomycosis treatments are included in the SHI, increasing their accessibility and creating a wider market for treatments.
   
• Also, Germany has a markedly aging population. Older patients have a higher likelihood of suffering from onychomycosis because of poor circulation, a compromised immune system, and prolonged medication usage. This creates an increasing need for onychomycosis treatment in the country and is positive for market growth.
   

The onychomycosis treatment market in Asia Pacific is estimated to grow at a CAGR of 5.6% over the next few years.
 

• China's healthcare spending has been increasing as part of its "Healthy China 2030" initiative, which aims to improve healthcare access and quality. This increase in healthcare expenditure is creating better access to medications, including treatments for onychomycosis.
   
• Moreover, conditions such as diabetes and obesity, which are prevalent in China, increase the risk of developing onychomycosis. With the rise in these chronic diseases, more individuals are prone to fungal infections, leading to a higher demand for treatment.
   
• Furthermore, the expansion of dermatology clinics in both urban and rural China has provided more access to diagnosis and treatment of onychomycosis. These clinics are increasingly adopting modern equipment and technologies to treat nail fungal infections.
   

Brazil's onychomycosis treatment market is projected to witness significant growth in Latin America market in the coming years.
 

• Brazil's aging population is expanding, leading to a higher number of onychomycosis cases and, consequently, a greater need for treatments.
   
• Furthermore, the expanding dermatology clinics and podiatry services in Brazil driven by investments in healthcare infrastructure drives the market growth. For instance, Brazil had over 10,000 registered dermatologists in 2024, the highest number in Latin America, promoting better diagnosis and treatment availability for onychomycosis.
   
• Additionally, government initiatives such as Sistema Unico de Saude (SUS) ensure free or low-cost treatment for dermatological conditions, including onychomycosis, increasing market penetration in rural and underserved areas.
   

Saudi Arabia onychomycosis treatment market is witnessing substantial growth in the Middle East and African market.
 

• The Saudi government has invested heavily in healthcare through its Vision 2030 initiative, which aims to improve the healthcare system. In addition, there is growing adoption of laser therapies, topical treatments, and oral antifungals in Saudi Arabia, driven by technological advancements in the healthcare sector boosting the market for onychomycosis treatment.
   
• Moreover, higher disposable incomes allow more people to seek private dermatology treatments. Additionally, Saudi Arabia is positioning itself as a medical tourism hub, attracting patients from neighboring regions for dermatological care that supports the growth of the market.
   

Onychomycosis Treatment Market Share

The top 5 companies in the market, such as Novartis, Pfizer, Bausch Health Sciences, Galderma Laboratories, and Dr. Reddy’s accounting for approximately 55% of the market share. Companies in the market maintain their competitive edge through innovations in diagnostic technologies, antifungal therapies, and AI-assisted healthcare solutions. With growing demand for specialized care, firms are expanding their portfolios to include precision diagnostic tools, advanced drug delivery systems, and personalized treatment regimens aimed at improving therapeutic efficacy and patient outcomes. For instance, leading players such as Bausch Health and Galderma are investing in next-generation topical and oral antifungals, while others focus on integrating AI-driven diagnostics and real-time treatment monitoring. These advancements are not only enhancing clinical accuracy but also accelerating market growth and intensifying competition across the sector. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.
 

Onychomycosis Treatment Market Companies

Few of the prominent players operating in the onychomycosis treatment industry include:

• Azilda Family Foot Care
• Bausch Health Sciences
• Dr. Reddy's Laboratories
• Galderma Laboratories
• GlaxoSmithKline
• Johnson & Johnson Services
• Kaken Pharmaceuticals
• Merz Pharma
• Moberg Pharma
• Novartis
• Pfizer
• Skin Logic Aesthetics
• South Charlotte General and Vascular Surgery
• Taro Pharmaceuticals 
   

To stay competitive, key players are investing in research and development, partnerships, and collaborations to launch new onychomycosis solutions.
 

• Companies such as Laboratorio Reig Jofre are transforming onychomycosis treatment by introducing new products in the market for better efficiency. REIG JOFRE launches a medicinal nail lacquer for onychomycosis with Ciclotech the new patented trans-ungueal release technology. These advancements are fostering increased competition, creating awareness, and stimulating growth across the market.
   
• Moreover, Almirall, S.A. (ALM), a global pharmaceutical company announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia.
   
• Moberg Pharma AB announced that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). Moberg Pharma is a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. 
   

Onychomycosis Treatment Industry News

• In February 2024, Moberg Pharma AB's marketing partner in Sweden, Allderma AB, launched sales of MOB-015 under the brand name Terclara. The product has garnered strong interest from pharmacies, reflecting significant demand for Moberg Pharma’s nail fungus treatment.
   
• In January 2024, Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis. This helped the company expand its product range.
   
• In November 2022, REIG JOFRE, Spanish pharmaceutical company launches a medicated nail lacquer for onychomycosis developed by its innovation team, manufactured at the Barcelona plant with CicloTech, the new patented trans-ungual release technology. This helped the company expand its sales in Europe.
   

The onychomycosis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Drugs
  • Oral antifungal drugs
  • Topical antifungal drugs 
• Laser and photodynamic therapy
• Surgery

Market, By Disease Type

• Distal subungual onychomycosis
• Proximal subungual onychomycosis
• White superficial onychomycosis
• Other disease types

Market, By Gender

• Male
• Female

Market, By End Use

• Hospitals
• Dermatology clinics
• Homecare settings
• Ambulatory surgical centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE